|
Table 2: Characteristics of included randomized controlled trials involving ESA with intravenous iron vis-a-vis iron therapies. |
|||||||
|
Study |
Total number of participants |
Preoperative haemoglobin (g/l) |
Surgery |
Intervention |
Comparator |
Pre or postoperative administration |
Measured outcomes |
|
Bernabeu- Wittel, 2016 |
306 |
9 to 12 |
Osteoporotic hip fracture |
EPO (40,000 IU) with IV iron (n = 100) |
Placebo with IV iron (n = 103) Placebo with EPO (n = 100) EPO (40,000 IU) with intravenous iron (n = 100) |
Pre and postoperative administration |
1. Number of red blood cell transfusions 2. Survival 3. Hemoglobin 4. Health quality related measures |
|
Kateros, 2010 |
79 |
< 13 |
Intertrochanteric fracture |
EPO (20,000 IU) with IV iron (n = 38) |
Placebo with IV iron (n = 41) |
Pre and postoperative administration |
1. Blood loss 2. Transfusions 3. Hemoglobin 4. Platelets |
|
Olijhoek, 2001 |
110 |
10 to 13 |
Elective orthopedic surgery |
EPO (84,000 IU) with IV iron (n = 29) |
EPO (20,000 IU) with oral iron (n = 29) Placebo with IV iron (n = 25) Placebo with oral iron (n = 27) |
Preoperative only |
1. Hemoglobin 2. Iron studies 3. Thromboembolic events |